Journal Information
Vol. 42. Issue S2.
Pages 63-64 (November 2020)
Download PDF
More article options
Vol. 42. Issue S2.
Pages 63-64 (November 2020)
Open Access
R.M. Cameloa,b,c, B.P. Duarteb, M.C.B. Mourab, C.C. Deelderc,d, N.C.M. Costab, I.M. Costab, C.G.P. Roncalb, A.M. Vanderleib, T.M.R. Guimaraesb, S. Gouwc, S.M. Rezendea, J.V.D. Bomc,d
a Ciências Aplicadas à Saude do Adulto, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, MG, Brazil
b Fundação de Hematologia e Hemoterapia de Pernambuco (Hemope), Recife, PE, Brazil
c Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, Netherlands
d Centre for Clinical Transfusion Research, Sanquin/Leiden University Medical Center, Leiden, Netherlands
Article information
Full Text

Since the introduction of episodic and prophylaxis treatment with safer products, the life expectancy of people with haemophilia (PwH) enhanced considerably. This comes with an increasing number of older PwH and with associated diseases, such as cardiovascular disease (CVD). HemoCardio was a cross-sectional study aimed to describe CVD risk factors among North-eastern Brazilian PwH. Male PwH 30 years or older were interviewed, had physical examinations, and provided blood samples. CVD risk scores were estimated according the Framingham Risk Score (FRS) tool. This tool predicts the 10-year risk of major CVD events (coronary disease–chronic arterial disease, stroke, peripheral obstructive arterial disease, or heart failure). The variables collected are described in Table 1. The estimated FRS was categorized into high- (> 20%), intermediate- (5-20%) and low-risk (< 5%). We classified all PwH with a history of coronary artery, cerebrovascular, or peripheral obstructive atherosclerotic disease, with subclinical (i.e., documented by diagnostic methodology) or clinical manifestations (CVD events); arterial revascularization procedures; diabetes mellitus; or CKD into the high-risk category regardless of the FRS estimation. Furthermore, individuals with an estimated intermediate-risk who had metabolic syndrome or a family history of premature CVD were recategorized as high-risk. Patients with an estimated low-risk with a positive family history of premature CVD were reclassified to the intermediate-risk category. Eighty-two PwH were included, of whom 83% had haemophilia A and half had severe disease. Median age at study entry was 43.0 years [interquartile range IQR, 36.0-51.3]. Obesity, arterial hypertension, and diabetes frequencies were 16%, 60% and 16%, respectively. Hypertriglyceridaemia, hypercholesterolaemia and hypoHDLaemia were present in 18%, 41% and 30%, respectively. Metabolic syndrome was present in 37%. Major electrocardiographic changes were described in 30%. There were 24/62 (39%) PwH with high-risk of developing cardiovascular events in the next 10 years, according to the FRS. Several reports of Brazilian general male population described a prevalence of high-risk FRS about 12%-13%. In conclusion, our findings suggest a relatively high prevalence of CVD risk factors and associated CVD risk score among men with haemophilia compared with the general male population.

Hematology, Transfusion and Cell Therapy

Subscribe to our newsletter

Article options